The initial success of Viagra undeniably reshaped the medication landscape, but placing funds in companies strongly reliant on unbranded versions presents a complex picture. Despite early returns were substantial, the expiration of patents and the appearance of less expensive alternatives have eroded the customer base. Consequently, a thorough anal